MYCN and neuroblastoma: Despite multimodal therapy including chemotherapy, surgery, radiotherapy, myeloablative therapy with autologous transplant, and immunotherapy, survival rates for MYCN‐amplified neuroblastoma patients remain poor [1, 2].